Safety Study of XP12B in Women With Menorrhagia

PHASE3CompletedINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
MenorrhagiaHeavy Menstrual Bleeding
Interventions
DRUG

Tranexamic acid tablets (XP12B)

Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation

Trial Locations (59)

13790

Investigative Site, Johnson City

15090

Investigative Site, Wexford

19104

Investigative Site, Philadelphia

23507

Investigative Site, Norfolk

27103

Investigative Site, Winston-Salem

27710

Investigative Site, Durham

28209

Investigative Site, Charlotte

29201

Investigative Site, Columbia

30005

Investigative Site, Alpharetta

30075

Investigative Site, Roswell

31405

Investigative Site, Savannah

31406

Investigative Site, Savannah

33186

Investigative Site, Miami

33407

Investigative Site, West Palm Beach

33409

Investigative Site, West Palm Beach

33781

Investigative Site, Pinellas Park

33916

Investigative Site, Fort Myers

34292

Investigative Site, Venice

34471

Investigative Site, Ocala

34652

Investigative Site, New Port Richey

35235

Investigative Site, Birmingham

36106

Investigative Site, Montgomery

36608

Investigative Site, Mobile

37203

Investigative Site, Nashville

37208

Investigative Site, Nashville

40291

Investigative Site, Louisville

40536

Investigative Site, Lexington

43614

Investigative Site, Toledo

45249

Investigative Site, Cincinnati

45267

Investigative Site, Cincinnati

46250

Investigative Site, Indianapolis

46601

Investigative Site, South Bend

47713

Investigative Site, Evansville

49024

Investigative Site, Portage

55318

Investigative Site, Chaska

59102

Investigative Site, Billings

61820

Investigative Site, Champaign

63110

Investigative Site, St Louis

63117

Investigative Site, St Louis

63141

Investigative Site, St Louis

66210

Investigative Site, Overland Park

68131

Investigative Site, Omaha

71103

Investigative Site, Shreveport

72205

Investigative Site, Little Rock

72401

Investigative Site, Jonesboro

77030

Investigative Site, Houston

80202

Investigative Site, Denver

80909

Investigative Site, Colorado Springs

83702

Investigative Site, Boise

85032

Investigative Site, Phoenix

85035

Investigative Site, Phoenix

87102

Investigative Site, Albuquerque

89030

Investigative Site, Las Vegas

89128

Investigative Site, Las Vegas

92103

Investigative Site, San Diego

92108

Investigative Site, San Diego

98105

Investigative Site, Seattle

98405

Investigative Site, Tacoma

08057

Investigative Site, Moorestown

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT00113568 - Safety Study of XP12B in Women With Menorrhagia | Biotech Hunter | Biotech Hunter